TOKYO - The Japan Pharmaceutical Manufacturers Association on Friday opposed U.S. support for a temporary waiver of coronavirus vaccine patent rights held by pharmaceutical companies, saying such a move could exacerbate global shortages of vital components for vaccines and stoke anxiety about product quality.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
